A growing medtech role in NHS copayment reforms?
This article was originally published in Clinica
Executive Summary
UK plans unveiled yesterday to expand access to NHS treatments and to allow private treatment to run in parallel to NHS care, enabling patients to have an active role in embracing innovative – and potentially more costly – treatments, should increasingly impinge on access to innovative medical technology too. So suggests the UK-based pan-regional lobby association, the Medical Technology Group (MTG), in recommendations submitted to the House of Commons health select committee (HSC), as part of an inquiry into patient safety*.